




April 2009



Chaired by James D. Watson
Registration & further information:
www.fchampalimaud.org
cancer2009@fchampalimaud.org
Invited Speakers:
PAUL MARKS ^{MSKCC} Memorial Sloan-Kettering Cancer Center
ALAN ASHWORTH ^{ICR} Institute of Cancer Research
RAGHU KALLURI ^{BIDMC} Beth Israel Deaconess Medical Center
MARIA BLASCO ^{CSIC} CNIO
CHARLES SAWYERS ^{MSKCC} Memorial Sloan-Kettering Cancer Center
BRUCE PONDER ^{CRUK} Cancer Research U.K.
JOSÉ BASELGA ^{VIO} Vall d'Hebron Institute of Oncology
LEE NADLER ^{DFCI} Dana-Farber Cancer Institute
YOEL KLOOG ^{Tel Aviv} Tel Aviv University
HEDVIG HRICAK ^{MSKCC} Memorial Sloan-Kettering Cancer Center
GIOVANNI MORRONE ^{UNICAT} University of Catanzaro
PETER JONES ^{USC} University of Southern California

Champalimaud
**CANCER
RESEARCH
SYMPOSIUM**
May 20th 2009
Lisbon Portugal



CF Announces Cancer Research Symposium

The Champalimaud Foundation is pleased to announce the Champalimaud Cancer Research Symposium, to be held in Lisbon, Portugal, on May 20th 2009. The meeting will be chaired by the Nobel Laureate, **James Watson** (photo, top-right) and will aim to share perspectives on the field from some of the world's leading cancer research specialists.

Invited Speakers:

Bruce Ponder, Cancer Research U.K.: "The role of genes in shaping our risk of disease: lessons from cancer"

Lee Nadler, Dana-Farber Cancer Institute: "Inflammation and cancer progression"

Raghu Kalluri, Beth Israel Deaconess Medical Center: "The rate of cancer progression and metastasis is controlled by tumor microenvironment"

Peter Jones, University of Southern California: "Epigenetic Therapy"

José Baselga, Vall d'Hebron Institute of Oncology: Talk title to be confirmed

Alan Ashworth, Institute of Cancer Research: "Synthetic lethal approaches to the development of new therapies targeting DNA repair deficiencies in cancer"

Hedvig Hricak, Memorial Sloan-Kettering Cancer Center

(MSKCC): "New horizons in oncologic imaging"

Charles Sawyers, MSKCC: "Novel approaches to anti-androgen therapy"

Paul Marks, MSKCC: "Histone deacetylase inhibitors – from bench to bedside"

Yoel Kloog, Tel Aviv University: "Design of new Ras inhibitor salirasib: from concept to mechanism of action and phase 1 trials"

Maria Blasco, Spanish National Cancer Research Centre: "Role of telomeres in cancer and aging"

Giovanni Morrone, University of Catanzaro: "Turning stem cells bad: dissection of leukaemogenesis through gene transfer in human haematopoietic stem cells"

Programme information and online registration are available at www.fchampalimaud.org/cancer.

The Symposium marks the continuation of the Champalimaud Foundation's commitment to cancer research, which has already included hosting a thinktank at Cold Spring Harbor's prestigious Banbury Center in October 2007. More recently, in 2008, the Foundation joined in collaboration with the Calouste Gulbenkian Foundation to support oncological specialists in a programme of advanced medical training. In addition, plans are already well

underway for the Champalimaud Cancer Research Programme which will support translational research of excellence. The Programme will be later housed in the Champalimaud Centre for the Unknown, due to open in October 2010.

The Champalimaud Cancer Research Symposium will be followed by the second annual meeting of the Champalimaud Foundation's Scientific Committee. The meeting will once again be chaired by the co-discoverer of the DNA molecule, **James Watson**, in his capacity as Head of the Committee. Dr. Watson is joined on the Committee by some of the world's most distinguished figures in science and medicine. They are: **Prof. Alan Ashworth**, from the Breakthrough Breast Cancer Research Centre in the U.K.; **Prof. Mark Bear**, Director of the Picower Center for Learning and Memory at M.I.T.; **Dr Ronald Blasberg** Head of the NeuroOncology PET Programme at the Memorial Sloan-Kettering Cancer Center in New York; **Dr. Maria Blasco**, Vice-Director of the Spanish National Cancer Research Centre; **Dr. Barry Dickson**, Scientific Director at the Austrian Institute of Molecular Pathology; **Dr Paul Marks**, former President of the Memorial Sloan-Kettering Cancer Centre in New York; **Prof. J. Anthony Movshon**, Director of the Center for Neural Science at New York University; **Prof. Sir Keith Peters**, President of the Academy of Medical Sciences, U.K.; **Prof. Martin Raff**, from University College London; **Prof. Susumu Tonegawa**, Nobel Laureate and Director of the RIKEN-MIT Neuroscience Research Center.

Champalimaud Day at LV Prasad Eye Institute



Prof. Balasubramanian, Director of the Champalimaud Foundation's C-TRACER facility

The Champalimaud Foundation celebrated the first anniversary of the C-TRACER facility by holding the Champalimaud Day Seminar at the LV Prasad Eye Institute (LVPEI), in Hyderabad, India. During a fascinating day of talks, Executive Committee member, **João Botelho**, stressed the importance of partnership and collaboration. These words were echoed by **Prof. Balasubramanian** who opened the symposium in his role as Head of the C-TRACER team and Director of Research at LVPEI. The symposium audience heard updates on the cutting-edge stem cell and eye genetics work of the C-TRACER facility and keynote talks were given by **Dr. VS Chauhan** (International Centre for Genetic Engineering and Biotechnology), **Dr. WM Bourne** (Mayo Clinic), **Dr. K Vijay Raghavan** (National Centre for Biological Sciences, Bangalore) and **Dr. Jeremy Nathans**, joint winner of the 2008 António Champalimaud Vision Award (Johns Hopkins

University).

The Champalimaud Translational Centre of Eye Research (C-TRACER) was inaugurated on January 30th 2008, following an historic agreement between the Champalimaud Foundation and the LV Prasad Eye Institute, in Hyderabad, India. C-TRACER conducts stem cell research to find novel solutions to corneal and retinal disorders. In addition, the team is working to develop C-TRACER as an exportable model of translational science which can bring the benefits of this revolutionary work to African Lusophone countries. Such is the impact of these stem cell techniques that the newspaper, India Today, recently named the work of C-TRACER scientists, **Drs Sangwan** and **Vemuganti** as being among India's top 10 medical miracles.

Construction continues on CF Centre

Construction continues on the Champalimaud Foundation's new centre for biomedical research, The Champalimaud Centre for the Unknown. Following the symbolic ceremony on October 5th 2008, when the Prime Minister of Portugal laid the first brick, work on the centre has developed rapidly.



Housing state-of-the-art facilities, the Champalimaud Centre for the Unknown will foster cutting-edge research in neuroscience and cancer and will open on October 5th 2010 in Lisbon.



Follow construction of the Champalimaud Centre for the Unknown at <http://www.fchampalimaud.org/care-research/cf-research-institute/construction-of-cf-research-centre/>.